Loading company
Loading
Latest annual · FY2025
Millions- Free cash flow
- (135)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 4
- Operating income
- (26)
- Net income
- (25)
Voyager Therapeutics, Inc. (VYGR) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $40.4 million | $80 million | -49.5% | 10-K 2026-03-09 · proof |
| Operating income | -$131.8 million | -$83.3 million | 10-K 2026-03-09 · proof | |
| Net income | -$119.7 million | -$65 million | 10-K 2026-03-09 · proof | |
| Cash from operating activities | -$132.5 million | -$15.3 million | 10-K 2026-03-09 · proof | |
| Free cash flow | -$135.1 million | -$18.8 million | 10-K 2026-03-09 · proof | |
| Total assets | $252.3 million | $393.1 million | -35.8% | 10-K 2026-03-09 · proof |
| Total liabilities | $56.2 million | $93.3 million | -39.8% | 10-K 2026-03-09 · proof |
| Cash and cash equivalents | $65.3 million | $71.4 million | -8.5% | 10-K 2026-03-09 · proof |
- What was Voyager Therapeutics, Inc. (VYGR)'s revenue in fiscal 2025?
- Voyager Therapeutics, Inc. (VYGR) reported revenue of $40.4 million for fiscal 2025 (the year ended Dec 31, 2025), against $80 million the year before (-49.5%). Source: the 10-K filed with the SEC on Mar 9, 2026. SEC
- What was Voyager Therapeutics, Inc. (VYGR)'s operating income in fiscal 2025?
- Voyager Therapeutics, Inc. (VYGR) reported operating income of -$131.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -$83.3 million the year before. Source: the 10-K filed with the SEC on Mar 9, 2026. SEC
- What was Voyager Therapeutics, Inc. (VYGR)'s net income in fiscal 2025?
- Voyager Therapeutics, Inc. (VYGR) reported net income of -$119.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$65 million the year before. Source: the 10-K filed with the SEC on Mar 9, 2026. SEC
- What was Voyager Therapeutics, Inc. (VYGR)'s cash from operating activities in fiscal 2025?
- Voyager Therapeutics, Inc. (VYGR) reported cash from operating activities of -$132.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$15.3 million the year before. Source: the 10-K filed with the SEC on Mar 9, 2026. SEC
- What was Voyager Therapeutics, Inc. (VYGR)'s free cash flow in fiscal 2025?
- Voyager Therapeutics, Inc. (VYGR) reported free cash flow of -$135.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$18.8 million the year before. Source: the 10-K filed with the SEC on Mar 9, 2026. SEC
- What are Voyager Therapeutics, Inc. (VYGR)'s total assets?
- As of Dec 31, 2025, Voyager Therapeutics, Inc. (VYGR) reported total assets of $252.3 million, against $393.1 million a year earlier (-35.8%). Source: the 10-K filed with the SEC on Mar 9, 2026. SEC
- What are Voyager Therapeutics, Inc. (VYGR)'s total liabilities?
- As of Dec 31, 2025, Voyager Therapeutics, Inc. (VYGR) reported total liabilities of $56.2 million, against $93.3 million a year earlier (-39.8%). Source: the 10-K filed with the SEC on Mar 9, 2026. SEC
- What are Voyager Therapeutics, Inc. (VYGR)'s cash and cash equivalents?
- As of Dec 31, 2025, Voyager Therapeutics, Inc. (VYGR) reported cash and cash equivalents of $65.3 million, against $71.4 million a year earlier (-8.5%). Source: the 10-K filed with the SEC on Mar 9, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:VYGR&period_type=annual&limit=5"Information only, not investment advice.